ESMO 2021 | CROWN update: results of an asian subgroup analysis

Qing Zhou, MD, PhD, of the Guangdong Lung Cancer Institute, Guangzhou, China, discusses the results of an Asian subgroup analysis of the CROWN study (NCT03052608), a global, randomized Phase III trial evaluating lorlatinib versus crizotinib in the first-line treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). The median progression-free survival rate for the crizotinib arm of the trial was consistent to that of previous trials. However, for lorlatinib, median progression-free survival has yet to be reached, highlighting the promise of lorlatinib in this patient population. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress